Trial reportFrontiers in immunology2019
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.
2 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph
Trial report in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics
A Roll-Over Observational Study for the Extended Follow-Up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP2020)
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and reservoir reduction in ART-treated adults with clade C infection: a 12-year follow-up study.Frontiers in immunology · 2026Trial
- Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions.Frontiers in immunology · 2026Article
- Tat-specific antibodies associated with better HIV-associated motor function.Scientific reports · 2025Article
- HIV-1 Tat: Molecular Switch in Viral Persistence and Emerging Technologies for Functional Cure.International journal of molecular sciences · 2025Review
- Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.International journal of molecular sciences · 2024Review
- Features of Tat Protein in HIV-1 Sub-Subtype A6 Variants Circulating in the Moscow Region, Russia.Viruses · 2023Article
- Recent advances in poor HIV immune reconstitution: what will the future look like?Frontiers in microbiology · 2023Review
- Article
- Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection.Disease markers · 2022Review
- New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.Archives of virology · 2021Review
- Anti-Tat immunity defines CD4EBioMedicine · 2021Article
- Review
- A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.Current HIV research · 2021Article
- HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication.International journal of molecular sciences · 2020Article
- Review
- Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 1 country.
Cecilia SgadariNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Paolo MoniniNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Antonella TripicianoNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Orietta PicconiNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Anna CasabiancaDepartment of Biomolecular Science, University of Urbino, Urbino, Italy.
Chiara OrlandiDepartment of Biomolecular Science, University of Urbino, Urbino, Italy.
Sonia MorettiNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Vittorio FrancavillaNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Angela ArancioNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Giovanni PanicciaNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Massimo CampagnaNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Stefania BellinoNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Marianna MeschiariDivision of Infectious Diseases, University Policlinic of Modena, Modena, Italy.
Silvia NozzaDivision of Infectious Diseases, San Raffaele Hospital, Milan, Italy.
Laura SighinolfiUnit of Infectious Diseases, University Hospital of Ferrara, Ferrara, Italy.
Alessandra LatiniUnit of Dermatology and Sexually Transmitted Diseases, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Antonio MuscatelloInfectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, University of Milan, Milan, Italy.
Annalisa SaracinoDivision of Infectious Diseases, University of Bari, Policlinic Hospital, Bari, Italy.
Massimo Di PietroUnit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy.
Massimo GalliInstitute of Tropical and Infectious Diseases, L. Sacco Hospital, University of Milan, Milan, Italy.
Aurelio CafaroNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Mauro MagnaniDepartment of Biomolecular Science, University of Urbino, Urbino, Italy.
Fabrizio EnsoliPathology and Microbiology, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Barbara EnsoliNational HIV/AIDS Research Center, Istituto Superiore di Sanità, Rome, Italy.
Istituto Superiore di Sanità · ITUniversity of Urbino · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITOspedale Santa Maria Annunziata · ITPoliclinico di Modena · ITUniversity of Bari Aldo Moro · ITUniversity of Ferrara · ITUniversity of Milan · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AIDS VaccinesAntibodies, ViralAnti-Retroviral AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDNA, ViralFollow-Up StudiesHIV-1HIV InfectionsHumanstat Gene Products, Human Immunodeficiency VirusViral LoadAIDS VaccinesAntibodies, ViralAnti-Retroviral AgentsDNA, Viraltat Gene Products, Human Immunodeficiency Virusanti-Tat antibodiescARTCD4+/CD8+ T-cell ratioCD4+ T cellsHIV reservoirsHIV therapeutic vaccineproviral DNATat
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04263207ClinicalTrials.gov
NCT05680948ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.